Related Experiment Video
Updated: Sep 14, 2025
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Clinical development complexity of TGF-β inhibition: From fibrosis to cancer immunotherapy
Gabriel Gallo-Oller1, María Isabel Guillén-Antonini1, Javier Dotor1
1DISIT Biotech SL, Fuenlabrada, Spain.
Abstract:
More than four decades have passed since the discovery of Transforming Growth Factor beta (TGF-β) in 1981, a pivotal cytokine with profound implications in cell biology and potential clinical interventions for physio-pathological processes including fibrosis, immune-related disorders, chronic infections, vascular alterations, and the progression of tumour growth through invasiveness and metastasis. However, the introduction of a specific inhibitor targeting this cytokine into the pharmaceutical market remains elusive. Various molecular entities and therapeutic strategies, including small molecules, peptides, recombinant proteins (such as specific antibodies), oligonucleotides, and cellular-based therapies have been devised and subjected to clinical trials. These target the specific TGF-β molecular pathway, either directly or indirectly. The combination of different drug types, routes of administration, and clinical indications has generated substantial data, emphasizing significant variability in patient outcomes. Efforts to enhance the effectiveness of cancer immunotherapy by combining TGF-β inhibitors with other drugs and modulating complementary molecular targets have been explored over the past few decades. This approach aims to translate the promising preclinical efficacy of TGF-β blockade into commercially available drugs that are suitable for a broad spectrum of clinical indications. However, a clear path to address the lack of discernible efficacy and overcome the associated marketing challenges has not yet emerged. This review provides a comprehensive overview of the clinical development and emerging trends in TGF-β inhibitors and modulatory strategies, offering novel perspectives for addressing this persistent challenge.
Insights
Transforming Growth Factor beta (TGF-β) inhibitors show promise for various diseases but face challenges in clinical efficacy and market approval. Further research is needed to overcome these hurdles for therapeutic application.
Area of Science:
- Cell Biology
- Immunology
- Oncology
- Pharmacology
Background:
- Transforming Growth Factor beta (TGF-β) is a key cytokine discovered in 1981, crucial in cell biology and implicated in numerous pathological processes.
- Despite extensive research and clinical trials for conditions like fibrosis, immune disorders, and cancer metastasis, a specific TGF-β inhibitor has yet to reach the pharmaceutical market.
- Therapeutic strategies targeting the TGF-β pathway include small molecules, peptides, antibodies, oligonucleotides, and cellular therapies, with varied outcomes.
Purpose of the Study:
- To provide a comprehensive overview of the clinical development of TGF-β inhibitors.
- To review emerging trends and novel strategies in TGF-β modulation.
- To offer perspectives on overcoming challenges in TGF-β inhibitor efficacy and market introduction.
Main Methods:
- Review of clinical trial data for various TGF-β inhibitors and modulatory strategies.
- Analysis of combination therapies, including TGF-β inhibitors with other drugs and complementary molecular targets.
- Examination of challenges related to patient outcome variability and market approval.
Main Results:
- Substantial data from clinical trials show significant variability in patient outcomes with current TGF-β inhibitors.
- Combination therapies, particularly for cancer immunotherapy, have been explored to enhance efficacy.
- Despite promising preclinical data, a clear path to discernible clinical efficacy and market success for TGF-β inhibitors remains elusive.
Conclusions:
- TGF-β inhibitors hold significant therapeutic potential across diverse medical fields.
- Overcoming challenges in clinical efficacy and market accessibility is critical for realizing the potential of TGF-β-targeted therapies.
- Novel perspectives and strategies are needed to translate preclinical promise into approved pharmaceutical products.
Related Concept Videos
01:16TGF - β Signaling Pathway
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment